Report error Found 127 Enz. Inhib. hit(s) with all data for entry = 50011667
Affinity DataIC50: 4nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 7nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Antagonist activity at RORgamma in human whole blood derived CD4-positive T cells assessed as inhibition of IL-17 secretion from differentiated Th17 ...More data for this Ligand-Target Pair
Affinity DataIC50: 8.40nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 9.90nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:Antagonist activity at RORgamma in human whole blood derived CD4-positive T cells assessed as inhibition of IL-17 secretion from differentiated Th17 ...More data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 14nMAssay Description:Antagonist activity at RORgamma in human whole blood derived CD4-positive T cells assessed as inhibition of IL-17 secretion from differentiated Th17 ...More data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 16nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 16nMAssay Description:Antagonist activity at RORgamma in human whole blood derived CD4-positive T cells assessed as inhibition of IL-17 secretion from differentiated Th17 ...More data for this Ligand-Target Pair
Affinity DataIC50: 16nMAssay Description:Antagonist activity at RORgamma in human whole blood derived CD4-positive T cells assessed as inhibition of IL-17 secretion from differentiated Th17 ...More data for this Ligand-Target Pair
Affinity DataIC50: 19nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 21nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 21nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 22nMAssay Description:Antagonist activity at RORgamma in human whole blood derived CD4-positive T cells assessed as inhibition of IL-17 secretion from differentiated Th17 ...More data for this Ligand-Target Pair
Affinity DataIC50: 22nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 23nMAssay Description:Antagonist activity at RORgamma in human whole blood derived CD4-positive T cells assessed as inhibition of IL-17 secretion from differentiated Th17 ...More data for this Ligand-Target Pair
Affinity DataIC50: 24nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 26nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 27nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 28nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 28nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 32nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 32nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 34nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 40nMAssay Description:Antagonist activity at RORgamma in human whole blood derived CD4-positive T cells assessed as inhibition of IL-17 secretion from differentiated Th17 ...More data for this Ligand-Target Pair
Affinity DataIC50: 42nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 43nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as inhibition of IL-22 productionMore data for this Ligand-Target Pair
Affinity DataIC50: 44nMAssay Description:Antagonist activity at RORgamma in human whole blood derived CD4-positive T cells assessed as inhibition of IL-17 secretion from differentiated Th17 ...More data for this Ligand-Target Pair
Affinity DataIC50: 48nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 48nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 49nMAssay Description:Antagonist activity at RORgamma in human whole blood derived CD4-positive T cells assessed as inhibition of IL-17 secretion from differentiated Th17 ...More data for this Ligand-Target Pair
Affinity DataIC50: 58nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 71nMAssay Description:Antagonist activity at RORgamma in human whole blood derived CD4-positive T cells assessed as inhibition of IL-17 secretion from differentiated Th17 ...More data for this Ligand-Target Pair
Affinity DataIC50: 74nMAssay Description:Antagonist activity at GAL4 DBD-fused human RORgamma LBD expressed in pGL4.3 luc2P/GAL4UAS/hygro and pBIND transfected HEK293 cells assessed as inhib...More data for this Ligand-Target Pair
Affinity DataIC50: 80nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 90nMAssay Description:Antagonist activity at GAL4 DBD-fused human RORgamma LBD expressed in pGL4.3 luc2P/GAL4UAS/hygro and pBIND transfected HEK293 cells assessed as inhib...More data for this Ligand-Target Pair
Affinity DataIC50: 98nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 110nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 110nMAssay Description:Antagonist activity at GAL4 DBD-fused human RORgamma LBD expressed in pGL4.3 luc2P/GAL4UAS/hygro and pBIND transfected HEK293 cells assessed as inhib...More data for this Ligand-Target Pair
Affinity DataIC50: 110nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 110nMAssay Description:Antagonist activity at GAL4 DBD-fused human RORgamma LBD expressed in pGL4.3 luc2P/GAL4UAS/hygro and pBIND transfected HEK293 cells assessed as inhib...More data for this Ligand-Target Pair
Affinity DataIC50: 120nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 120nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 120nMAssay Description:Antagonist activity at RORgamma in human PBMC assessed as reduction in anti-CD3/IL-23 stimulated IL-17 level measured after 3 days by MSD assayMore data for this Ligand-Target Pair
Affinity DataIC50: 130nMAssay Description:Antagonist activity at GAL4 DBD-fused human RORgamma LBD expressed in pGL4.3 luc2P/GAL4UAS/hygro and pBIND transfected HEK293 cells assessed as inhib...More data for this Ligand-Target Pair
